Table 3.
PPI in SPCR projects, by study design, health condition, population and population age
| Projects (Grant applications) | Projects with evidence of PPI in developing the grant application (N = 200) |
Projects with evidence of plans for PPI during the study in the grant application (N = 200) | Projects (Annual/ Final Reports)a | Projects with evidence of PPI reported in annual/final reports (N = 181) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | (Relative %)b | n | (%) | (Relative %)b | n | (%) | n | (%) | (Relative %)c | |
| All Projects | 200 | (100) | 47 | (23.5) | 113 | (56.5) | 181 | (181) | 83 | (46.1) | |||
| Study Design | |||||||||||||
| Mixed methods | 47 | (23.5) | 15 | (7.5) | (31.9) | 30 | (15.0) | (63.8) | 39 | (21.5) | 24 | (13.3) | (61.5) |
| Qualitative | 36 | (18.0) | 9 | (4.5) | (25.0) | 23 | (11.5) | (63.9) | 30 | (16.6) | 17 | (9.4) | (56.7) |
| Longitudinal cohort | 29 | (14.5) | 5 | (2.5) | (17.2) | 18 | (9.0) | (62.1) | 29 | (16.0) | 11 | (6.1) | (37.9) |
| Intervention trial | 25 | (12.5) | 6 | (3.0) | (24.0) | 15 | (7.5) | (60.0) | 23 | (12.7) | 14 | (7.7) | (60.9) |
| Systematic reviews | 17 | (8.5) | 2 | (1.0) | (11.8) | 7 | (3.5) | (0.0) | 17 | (9.4) | 2 | (1.1) | (11.8) |
| Retrospective cohort | 13 | (6.5) | 2 | (1.0) | (15.4) | 4 | (2.0) | (30.8) | 13 | (7.2) | 3 | (1.7) | (23.1) |
| Secondary analysis | 8 | (4.0) | 0 | (0.0) | (0.0) | 4 | (2.0) | (50.0) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| Cross sectional | 7 | (3.5) | 4 | (2.0) | (57.1) | 3 | (1.5) | (42.9) | 7 | (3.9) | 4 | (2.2) | (57.1) |
| Methodological | 5 | (2.5) | 1 | (0.5) | (20.0) | 4 | (2.0) | (80.0) | 4 | (2.2) | 1 | (0.6) | (25.0) |
| Case control | 4 | (2.0) | 0 | (0.0) | (0.0) | 1 | (0.5) | (25.0) | 3 | (1.7) | 0 | 0 | (0.0) |
| Multi-stage studyd | 4 | (2.0) | 2 | (1.0) | (50.0) | 2 | (1.0) | (50.0) | 2 | (1.1) | 2 | (1.1) | (100) |
| Individual participant meta analysis | 3 | (1.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (33.3) | 2 | (1.1) | 1 | (0.6) | (50.0) |
| Othere | 2 | (1.0) | 1 | (0.5) | (50.0) | 1 | (0.5) | (50.0) | 4 | (2.2) | 2 | (1.1) | (50.0) |
| Health Condition Under Study | |||||||||||||
| General Health | 28 | (14.0) | 9 | (4.5) | (32.1) | 14 | (7.0) | (50.0) | 22 | (12.2) | 9 | (0.0) | (40.9) |
| Cardiovascular | 27 | (13.5) | 4 | (2.0) | (14.8) | 16 | (8.0) | (59.3) | 28 | (15.5) | 10 | (5.5) | (35.7) |
| Mental Health | 21 | (10.5) | 5 | (2.5) | (23.8) | 12 | (6.0) | (57.1) | 17 | (9.4) | 11 | (6.1) | (64.7) |
| Cancer | 16 | (8.0) | 7 | (3.5) | (43.8) | 8 | (4.0) | (50.0) | 16 | (8.8) | 10 | (5.5) | (62.5) |
| Metabolic and Endocrine | 14 | (7.0) | 1 | (0.5) | (7.1) | 6 | (3.0) | (42.9) | 16 | (8.8) | 9 | (5.0) | (56.3) |
| Musculoskeletal | 14 | (7.0) | 3 | (1.5) | (21.4) | 6 | (3.0) | (42.9) | 13 | (7.2) | 6 | (3.3) | (46.2) |
| Respiratory | 13 | (6.5) | 3 | (1.5) | (23.1) | 6 | (3.0) | (46.2) | 12 | (6.6) | 5 | (2.8) | (41.7) |
| Multimorbidity | 7 | (3.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (14.3) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| Stroke | 7 | (3.5) | 1 | (0.5) | (14.3) | 3 | (1.5) | (42.9) | 5 | (2.8) | 2 | (1.1) | (40.0) |
| Infection | 5 | (2.5) | 1 | (0.5) | (20.0) | 3 | (1.5) | (60.0) | 5 | (2.8) | 1 | (5.0) | (20.0) |
| Renal and Urogenital | 5 | (2.5) | 2 | (1.0) | (40.0) | 5 | (2.5) | (100) | 5 | (2.8) | 3 | (1.7) | (60.0) |
| Reproductive Health and Childbirth | 5 | (2.5) | 2 | (1.0) | (40.0) | 5 | (2.5) | (100) | 5 | (2.8) | 4 | (2.2) | (80.0) |
| Neurological | 3 | (1.5) | 0 | (0.0) | (0.0) | 3 | (1.5) | (100) | 1 | (0.6) | 1 | (0.6) | (100) |
| Cancer, Mental Health | 1 | (0.5) | 1 | (0.5) | (100) | 0 | (0.0) | (0.0) | 1 | (0.6) | 1 | (0.6) | (100) |
| Inflammatory and Immune System | 1 | (0.5) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 0 | (0.0) | 0 | (0.0) | |
| Oral and Gastrointestinal | 1 | (0.5) | 0 | (0.0) | (0.0) | 0 | (0.0) | (0.0) | 1 | (0.6) | 0 | (0.0) | (0.0) |
| Skin | 1 | (0.5) | 1 | (0.5) | (100) | 1 | (0.5) | (100) | 1 | (0.6) | 1 | (0.6) | (100) |
| Otherf | 31 | (15.5) | 7 | (3.5) | (22.6) | 24 | (12.0) | (77.4) | 23 | (12.7) | 8 | (4.4) | (34.8) |
| Study population | |||||||||||||
| Patients | 134 | (67.0) | 26 | (13.0) | (19.4) | 68 | (34.0) | (50.7) | 123 | (68.0) | 54 | (29.8) | (43.9) |
| Patients & HCPs | 37 | (18.5) | 11 | (5.5) | (29.7) | 24 | (12.0) | (64.9) | 31 | (17.1) | 20 | (11.0) | (64.5) |
| Healthcare professionals (HCPs) | 15 | (7.5) | 5 | (2.5) | (33.3) | 10 | (5.0) | (66.7) | 8 | (4.4) | 3 | (1.7) | (37.5) |
| General public | 13 | (6.5) | 5 | (2.5) | (38.5) | 10 | (5.0) | (76.9) | 15 | (8.3) | 7 | (3.9) | (46.7) |
| Carers | 1 | (0.5) | 0 | (0.0) | (0.0) | 1 | (0.5) | (100) | 1 | (0.6) | 0 | (0.0) | (0.0) |
| Study population age | |||||||||||||
| Unspecified | 93 | (46.5) | 19 | (9.5) | (20.4) | 54 | (27.0) | (58.1) | 83 | (45.9) | 35 | (19.9) | (43.4) |
| Adult (18+ years) | 89 | (44.5) | 24 | (12.0) | (27.0) | 50 | (25.0) | (56.2) | 83 | (45.9) | 42 | (23.2) | (50.6) |
| Adult and Children | 11 | (5.5) | 4 | (2.0) | (36.4) | 7 | (3.5) | (63.6) | 9 | (5.0) | 5 | (2.8) | (55.6) |
| Children and young adults (0–17 years)g | 7 | (3.5) | 0 | (0.0) | (0.0) | 2 | (1.0) | (28.6) | 6 | (3.3) | 1 | (0.6) | (16.7) |
aIncluded one project whose data on PPI was obtained from an SPCR poster
bPercentage relative to the number of projects in each category in grant applications
cPercentage relative to the number of projects in each category in annual/final reports
dMulti-stage studies included case control and intervention trial (1), cross sectional and longitudinal cohort (1), systematic review and longitudinal cohort (1), systematic review and secondary analysis
eIncluded projects to set up and maintain a SPCR PPI group (1) and a preliminary descriptive study (1)
fConditions not classified under the Health Research Classification System [24]
gIt was not always possible to determine the ages or age range of children from the study documentation. Sometimes, ages were provided, sometimes the documentation referred to ‘children’. So we have assumed children and young adults to be 17 and under